Lucid Diagnostics (NASDAQ:LUCD) & Alpha Tau Medical (NASDAQ:DRTS) Financial Survey

Alpha Tau Medical (NASDAQ:DRTS) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation.

Insider & Institutional Ownership

2.7% of Alpha Tau Medical shares are held by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are held by institutional investors. 39.5% of Alpha Tau Medical shares are held by insiders. Comparatively, 6.8% of Lucid Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Alpha Tau Medical and Lucid Diagnostics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Tau Medical	N/A	N/A	-$31.75 million	($0.52)	-13.92
Lucid Diagnostics	$4.35 million	43.68	-$45.53 million	($1.04)	-1.33

Alpha Tau Medical has higher earnings, but lower revenue than Lucid Diagnostics. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Alpha Tau Medical has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Alpha Tau Medical and Lucid Diagnostics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Tau Medical	1	1	2	0	2.25
Lucid Diagnostics	1	0	4	0	2.60

Alpha Tau Medical presently has a consensus target price of $8.00, indicating a potential upside of 10.50%. Lucid Diagnostics has a consensus target price of $3.94, indicating a potential upside of 185.33%. Given Lucid Diagnostics’ stronger consensus rating and higher possible upside, analysts plainly believe Lucid Diagnostics is more favorable than Alpha Tau Medical.

Profitability

This table compares Alpha Tau Medical and Lucid Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Tau Medical	N/A	-56.45%	-41.76%
Lucid Diagnostics	-1,418.39%	N/A	-96.99%

Summary

Lucid Diagnostics beats Alpha Tau Medical on 8 of the 13 factors compared between the two stocks.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

About Lucid Diagnostics

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.